Dimitrios (Dimitri) Makrakis (@dmakrakismd) 's Twitter Profile
Dimitrios (Dimitri) Makrakis

@dmakrakismd

MD, PGY-3 @jacobihosp @einsteinmed - GU Onc Research Fellow @UoWashington from @UOC_gr ๐Ÿ‡ฌ๐Ÿ‡ท๐Ÿ‡บ๐Ÿ‡ฒ

ID: 1302006230626512896

linkhttps://scholar.google.com/citations?user=NLuKUbsAAAAJ&hl=en calendar_today04-09-2020 22:11:10

298 Tweet

586 Followers

551 Following

Stepan M. Esagian, MD (@sm_esagian) 's Twitter Profile Photo

Absolutely thrilled to share that Iโ€™ve matched at MD Anderson for my hematology/oncology fellowship! Immensely grateful to my mentors for their unwavering support in helping me overcome the challenges faced by non-US IMGs and achieve this dream! #MatchDay #JacobiStrong

Absolutely thrilled to share that Iโ€™ve matched at MD Anderson for my hematology/oncology fellowship! Immensely grateful to my mentors for their unwavering support in helping me overcome the challenges faced by non-US IMGs and achieve this dream!  #MatchDay #JacobiStrong
Shilpa Gupta (@shilpaonc) 's Twitter Profile Photo

Marc-Olivier Timsit, MD, PhD ๐ŸŽ—๏ธ Petros Grivas Cleveland Clinic Karima Oualla, MD,MSc Nawfel MELLAS Agree ๐Ÿ’ฏAmazing discussion by Petros Grivas discussing nuances of IO-based perioperative tx in MIBC. Is pCR a relevant endpoint? Need to tease out neoadjuvant vs adjuvant contribution of IO instead of blanket approach. Deep dive into NIAGARA trial which he discussed at ESMO - Eur. Oncology

<a href="/UrologieParis/">Marc-Olivier Timsit, MD, PhD ๐ŸŽ—๏ธ</a> <a href="/PGrivasMDPhD/">Petros Grivas</a> <a href="/ClevelandClinic/">Cleveland Clinic</a> <a href="/karima_oualla/">Karima Oualla, MD,MSc</a> <a href="/NawfelMellas/">Nawfel MELLAS</a> Agree ๐Ÿ’ฏAmazing discussion by <a href="/PGrivasMDPhD/">Petros Grivas</a> discussing nuances of IO-based perioperative tx in MIBC. Is pCR a relevant endpoint? 
Need to tease out neoadjuvant vs adjuvant contribution of IO instead of blanket approach. 
Deep dive into NIAGARA trial which he discussed at <a href="/myESMO/">ESMO - Eur. Oncology</a>
Stepan M. Esagian, MD (@sm_esagian) 's Twitter Profile Photo

Truly honored to receive this recognition from Conquer Cancer, the ASCO Foundation! Excited to present our findings on cytoreductive nephrectomy utilization trends and disparities at ASCO #GU25. Grateful to my mentors and collaborators Pavlos Msaouel Dimitrios (Dimitri) Makrakis

Pavlos Msaouel (@pavlosmsaouel) 's Twitter Profile Photo

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/โ€ฆ The V Foundation for Cancer Research Chris Johnson Foundation Inc.

1/5 Sharing our <a href="/CCR_AACR/">Clinical Cancer Research</a> work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/โ€ฆ <a href="/TheVFoundation/">The V Foundation for Cancer Research</a> <a href="/renalmedullary/">Chris Johnson Foundation Inc.</a>
Petros Grivas (@pgrivasmdphd) 's Twitter Profile Photo

Join our GU dream team Fred Hutch Cancer Center UW Medicine dedicated to exceptional patient care, innovative research, education, outreach, career growth! We have 2 open positions, links below: apply.interfolio.com/165668 apply.interfolio.com/158802 Nicole D. Fleming MD Hsieh Lab Sarah P. Psutka MD MS Daniel Lin

UroToday.com (@urotoday) 's Twitter Profile Photo

Investigating PARP expression as a biomarker for targeted therapy in #ProstateCancer. Emmanuel Antonarakis Masonic Cancer Center, University of Minnesota sits down with Neeraj Agarwal Huntsman Cancer Institute to unpack how PARP1 expression could redefine PARP inhibitor use in prostate cancer. In BRCA2+ patients, high PARP1 = 100%

Investigating PARP expression as a biomarker for targeted therapy in #ProstateCancer. <a href="/EAntonarakis/">Emmanuel Antonarakis</a> <a href="/UMNCancer/">Masonic Cancer Center, University of Minnesota</a> sits down with <a href="/NeerajAgarwal/">Neeraj Agarwal</a> <a href="/huntsmancancer/">Huntsman Cancer Institute</a> to unpack how PARP1 expression could redefine PARP inhibitor use in prostate cancer. In BRCA2+ patients, high PARP1 = 100%
Jacobi Internal Medicine Chiefs (@jmcchiefs) 's Twitter Profile Photo

Our annual talent show night was a huge success! Amazing performances by our talented residents and tons of laughs along the way. Proud of our Jacobi family!

Our annual talent show night was a huge success!  Amazing performances by our talented residents and tons of laughs along the way. Proud of our Jacobi family!